{"brief_title": "A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine", "brief_summary": "The purpose of this clinical research study is to assess the safety and effectiveness of switching to entecavir compared to continued lamivudine in patients with chronic hepatitis B.", "condition": "Chronic Hepatitis B", "intervention_type": "Drug", "intervention_name": "Entecavir", "criteria": "- Male and female subjects =/> 16 years of age (or minimum age required in a given country) with history of HBeAg-positive chronic hepatitis B infection; - Incomplete response to current lamivudine therapy; - HBeAg-positive; - Absence of coinfection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis D virus (HDV); - Absence of other forms of liver disease e.g., alcoholic, autoimmune, biliary disease.", "gender": "All", "minimum_age": "16 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00036608.xml"}